Search

Your search keyword '"Vogelzang, N.J."' showing total 183 results
Start Over Author "Vogelzang, N.J."
183 results on '"Vogelzang, N.J."'

52. 793PD - Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations

Author

Abida, W., Bryce, A.H., Vogelzang, N.J., Amato, R.J., Percent, I., Shapiro, J.D., McDermott, R., Hussain, A., Patnaik, A., Petrylak, D., Ryan, C.J., Stanton, T., Zhang, J., Simmons, A.D., Despain, D., Collins, M., Golsorskhi, T., Scher, H.I., and Chowdhury, S.

Published
2018
Full Text
View/download PDF

53. 901P - Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045

Author

Bellmunt, J., de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J.L., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D., Choueiri, T.K., Necchi, A., Gerritsen, W.R., Gurney, H., Quinn, D.I., Culine, S., Sternberg, C.N., Jensen, E., Frenkl, T., Perini, R.F., and Bajorin, D.

Published
2018
Full Text
View/download PDF

54. 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA

Author

Amadori, D., primary, Rossetti, C., additional, Aglietta, M., additional, Messina, C., additional, Versari, A., additional, Vogelzang, N.J., additional, Sartor, A., additional, Coleman, R.E., additional, Govi, S., additional, Fang, F., additional, Skjorestad, I., additional, Nilsson, S., additional, and Parker, C., additional

Published
2015
Full Text
View/download PDF

56. 4BA A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC)

Author

Carducci, M., primary, Armstrong, A., additional, Pili, R., additional, Ng, S., additional, Huddart, R., additional, Agarwal, N., additional, Khvorostenko, D., additional, Lyulko, O., additional, Brize, A., additional, Vogelzang, N.J., additional, Delva, R., additional, Harza, M., additional, Thanos, A., additional, James, N., additional, Werbrouck, P., additional, Bögemann, M., additional, Hutson, T., additional, Milecki, P., additional, Nederman, T., additional, and Sternberg, C., additional

Published
2015
Full Text
View/download PDF

59. 672 Prior and concurrent use of abiraterone and enzalutamide with radium-223 dichloride (Ra-223) in US expanded access setting (EAP)

Author

Sartor, O., primary, Fernandez, D.C., additional, Morris, M.J., additional, Iagaru, A., additional, Brown, Jr A., additional, Almeida, F., additional, Sweeney, C., additional, Smith, M.R., additional, Dicker, A.P., additional, Wong, Y.N., additional, Shore, N., additional, Gratt, J., additional, Petrenciuc, O., additional, and Vogelzang, N.J., additional

Published
2015
Full Text
View/download PDF

60. LBA37_PR - Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial

Author

de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J-L., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D.P., Choueiri, T.K., Necchi, A., Gerritsen, W.R., Gurney, H., Quinn, D.I., Culine, S., Sternberg, C.N., Mai, Y., Puhlmann, M., Perini, R.F., Bellmunt, J., and Bajorin, D.F.

Published
2017
Full Text
View/download PDF

62. 851PD - Subgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator’s choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc)

Author

Petrylak, D., Vogelzang, N.J., Fradet, Y., Bajorin, D., de Wit, R., Vaughn, D.J., Lee, J-L., Fong, L., Climent, M.A., Necchi, A., Gerritsen, W.R., Gurney, H., Quinn, D.I., Culine, S., Sternberg, C.N., Jensen, E., Puhlmann, M., Perini, R., Bellmunt, J., and Choueiri, T.K.

Published
2017
Full Text
View/download PDF

64. P078 Further characterization of the effects on sequential treatment of docetaxel before or after radium-223 dichloride therapy in Castration-Resistant Prostate Cancer (CRPC) patients with symptomatic bone metastases included in the phase 3 ALSYMPCA trial

Author

Mellado, B., primary, Sartor, O., additional, Vogelzang, N.J., additional, Hoskin, P., additional, Nilsson, S., additional, Coleman, R.E., additional, Parker, C., additional, Wahba, M., additional, Haugen, I., additional, and Shore, N.D., additional

Published
2014
Full Text
View/download PDF

66. A Phase 1/2 Study of At13387, a Heat Shock Protein 90 (Hsp90) Inhibitor in Combination with Abiraterone Acetate (Aa) and Prednisone (P) in Patients (Pts) with Castration-Resistant Prostate Cancer (Mcrpc) No Longer Responding to Aa

Author

Ferraldeschi, R., primary, Slovin, S., additional, Hussain, S., additional, Saad, F., additional, Garcia, J., additional, Kabbinavar, F.F., additional, Uppal, N., additional, Vogelzang, N.J., additional, Poiesz, B.J., additional, Gelmann, E., additional, Picus, J., additional, Mahadevan, D., additional, Sundar, S., additional, Nikapota, A., additional, Pacey, S., additional, Oganesian, A., additional, Manlapaz-Espiritu, L., additional, Hao, Y., additional, Keer, H., additional, and de Bono, J., additional

Published
2014
Full Text
View/download PDF

67. A Randomized Phase 2 Study Evaluating Optimal Sequencing of Sipuleucel-T (Sip-T) and Androgen Deprivation Therapy (Adt) in Biochemically-Recurrent Prostate Cancer (Brpc): Variables that Correlate with Immune Response

Author

Drake, C.G., primary, Kibel, A.S., additional, Adams, G.W., additional, Karsh, L.I., additional, Elfiky, A., additional, Shore, N.D., additional, Vogelzang, N.J., additional, Corman, J.M., additional, Tyler, R.C., additional, McCoy, C., additional, Devries, T., additional, Sheikh, N., additional, and Antonarakis, E.S., additional

Published
2014
Full Text
View/download PDF

68. 980 A randomized phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC): Immune results with a focus on humoral responses

Author

Antonarakis, E.S., primary, Kibel, A.S., additional, Adams, G.W., additional, Karsh, L.I., additional, Elfiky, A., additional, Shore, N.D., additional, Vogelzang, N.J., additional, Corman, J.M., additional, Tyler, R.C., additional, McCoy, C., additional, DeVries, T., additional, Sheikh, N., additional, and Drake, C.G., additional

Published
2014
Full Text
View/download PDF

69. Current vaccination strategies for prostate cancer.

Author

Joniau, S., Abrahamsson, P.A., Bellmunt, J., Figdor, C.G., Hamdy, F., Verhagen, P., Vogelzang, N.J., Wirth, M., Poppel, H. van, Osanto, S., Joniau, S., Abrahamsson, P.A., Bellmunt, J., Figdor, C.G., Hamdy, F., Verhagen, P., Vogelzang, N.J., Wirth, M., Poppel, H. van, and Osanto, S.

Abstract

1 februari 2012, Item does not contain fulltext, CONTEXT: The first therapeutic cancer vaccine demonstrating effectiveness in a phase 3 study was approved by the US Food and Drug Administration on 29 April 2010. The pivotal trial demonstrated overall survival (OS) benefit in patients treated with antigen-loaded leukapheresis cells compared with a control infusion. Results of other prostate cancer (PCa) vaccination strategies are awaited, as this approach may herald a new era in the care for patients with advanced PCa. OBJECTIVE: Consider effectiveness and safety of vaccination strategies in the treatment of PCa. EVIDENCE ACQUISITION: We searched three bibliographic databases (January 1995 through October 2010) for randomised phase 2 and 3 studies of vaccination strategies for PCa based on predetermined relevant Medical Subject Heading terms and free text terms. EVIDENCE SYNTHESIS: Data from 3 randomised phase 3 and 10 randomised phase 2 vaccination trials are discussed with respect to clinical outcome in terms of progression-free survival and OS, toxicity, prostate-specific antigen (PSA) response, and immunologic response. Three phase 3 trials (D9901, D9902A, and D9902B) that enrolled a total of 737 patients, all controlled and double-blinded, tested the efficacy of sipuleucel-T. The largest of these three trials, called Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT), has demonstrated safety and effectiveness of sipuleucel-T (now marketed as Provenge) as measured by prolonged survival of 512 asymptomatic patients with metastatic castration-resistant PCa (mCRPC). The study showed a 4.1-mo median survival benefit in the sipuleucel-T vaccine-treated group compared with the control group (25.8 vs 21.7 mo; hazard ratio [HR]: 0.78; 95% confidence interval [CI], 0.62-0.98; p=0.032) and extended 3-yr survival (31.7% vs 23.0%). In contrast, two phase 3 vaccination trials with a whole-tumour-cell mixture of two PCa cell lines (GVAX) and testing GVAX either alone or in combination with chemotherapy versus chemo

Published
2012

73. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.

Author

Escudier, B., Roigas, J., Gillessen, S., Harmenberg, U., Srinivas, S., Mulder, S.F., Fountzilas, G., Peschel, C., Flodgren, P., Maneval, E.C., Chen, I., Vogelzang, N.J., Escudier, B., Roigas, J., Gillessen, S., Harmenberg, U., Srinivas, S., Mulder, S.F., Fountzilas, G., Peschel, C., Flodgren, P., Maneval, E.C., Chen, I., and Vogelzang, N.J.

Abstract

Contains fulltext : 81935.pdf (publisher's version ) (Closed access), PURPOSE: Sunitinib has demonstrated antitumor activity in metastatic renal cell carcinoma (mRCC) when given at 50 mg/d on a 4-weeks-on 2-weeks-off regimen. Herein, we report results of an open-label, multicenter phase II mRCC study of sunitinib administered on a continuous once-daily dosing regimen. PATIENTS AND METHODS: Eligibility criteria included histologically proven mRCC with measurable disease, failure of one prior cytokine regimen, and good performance status. Patients were randomly assigned to a sunitinib starting dose of 37.5 mg/d in the morning (AM) or evening (PM). RECIST-defined objective response rate (ORR) was the primary end point. Secondary end points included progression-free survival (PFS), overall survival (OS), adverse events (AEs), and quality-of-life measures. RESULTS: One hundred seven patients were randomly assigned to AM (n = 54) or PM (n = 53) dosing and on study for a median 8.3 months. Eighty-three patients discontinued, 65 due to disease progression and 16 because of AEs; two patients withdrew consent. Dosing was reduced to 25 mg/d in 46 patients (43%) due to grade 3/4 AEs. The most common grade 3 treatment-related AEs were asthenia/fatigue (16%), diarrhea (11%), hypertension (11%), hand-foot syndrome (9%), and anorexia (8%). ORR was 20% with a 7.2-month median response duration. Median PFS and OS were 8.2 and 19.8 months, respectively, at median follow-up of 26.4 months. Efficacy, tolerability, and quality-of-life results were similar between patients dosed in the AM or PM. CONCLUSION: Sunitinib 37.5 mg, administered on a continuous once-daily dosing regimen, has a manageable safety profile as second-line mRCC therapy, providing flexible dosing, which can be explored in combination studies.

Published
2009

75. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Author

Parker, C., primary, Nilsson, S., additional, Heinrich, D., additional, Helle, S.I., additional, O'Sullivan, J.M., additional, Fosså, S.D., additional, Chodacki, A., additional, Wiechno, P., additional, Logue, J., additional, Seke, M., additional, Widmark, A., additional, Johannessen, D.C., additional, Hoskin, P., additional, Bottomley, D., additional, James, N.D., additional, Solberg, A., additional, Syndikus, I., additional, Kliment, J., additional, Wedel, S., additional, Boehmer, S., additional, Dall'Oglio, M., additional, Franzén, L., additional, Coleman, R., additional, Vogelzang, N.J., additional, O'Bryan-Tear, C.G., additional, Staudacher, K., additional, Garcia-Vargas, J., additional, Shan, M., additional, Bruland, Ø.S., additional, and Sartor, O., additional

Published
2013
Full Text
View/download PDF

79. p53 Protein Expression Status and Recurrence in Men Treated With Radiation Therapy and Androgen Suppression Therapy for Higher Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study

Author

D'Amico, A.V., primary, Halabi, S., additional, Vollmer, R., additional, Loffredo, M., additional, McMahon, E., additional, Sanford, B., additional, Archer, L., additional, Vogelzang, N.J., additional, Small, E., additional, and Kantoff, P., additional

Published
2007
Full Text
View/download PDF

81. 174 Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and radiation (RT) for malignant pleural mesothelioma (MPM)

Author

Krug, L.M., primary, Pass, H.I., additional, Rusch, V.W., additional, Kindler, H.L., additional, Sugarbaker, D.J., additional, Rosenzweig, K.E., additional, Friedberg, J.S., additional, Raman, J., additional, Ye, Z., additional, Obasaju, C., additional, and Vogelzang, N.J., additional

Published
2006
Full Text
View/download PDF

83. 776P - A Phase 1/2 Study of At13387, a Heat Shock Protein 90 (Hsp90) Inhibitor in Combination with Abiraterone Acetate (Aa) and Prednisone (P) in Patients (Pts) with Castration-Resistant Prostate Cancer (Mcrpc) No Longer Responding to Aa

Author

Ferraldeschi, R., Slovin, S., Hussain, S., Saad, F., Garcia, J., Kabbinavar, F.F., Uppal, N., Vogelzang, N.J., Poiesz, B.J., Gelmann, E., Picus, J., Mahadevan, D., Sundar, S., Nikapota, A., Pacey, S., Oganesian, A., Manlapaz-Espiritu, L., Hao, Y., Keer, H., and de Bono, J.

Published
2014
Full Text
View/download PDF

88. 456 A randomized double-blind trial in 813 previously untreated metastatic prostate cancer (CaP) patients (PTS) comparing a new antiandrogen casodex® (bicalutamide) with eulexin (flutamide) in combination with luteinizing hormone releasing hormone analogue (LHRH-a) therapy

Author

Vogelzang, N.J., primary, Schellhammer, P.F., additional, Sharifi, R., additional, Block, N.L., additional, Soloway, M.S., additional, Venner, P.M., additional, Patterson, A.L., additional, Sarosdy, M.F., additional, Jones, J.A., additional, and Kolvenbag, G., additional

Published
1995
Full Text
View/download PDF

91. Bicalutamide in the Treatment of Advanced Prostatic Carcinoma: A Phase II Noncomparative Multicenter Trial Evaluating Safety, Efficacy and Long-Term Endocrine Effects of Monotherapy

Author

Soloway, M.S., Schellhammer, P.F., Smith, J.A.Jr., Chodak, G.W., Vogelzang, N.J., and Kennealey, G.T.

Abstract

Purpose: The safety, efficacy and pharmacokinetics of bicalutamide were investigated in 150 patients with stage D2 prostate cancer. Materials and Methods: Patients received 50 mg. bicalutamide daily in an open label multicenter North American trial. Results: The objective response rate (modified European Organization for Research in Cancer Therapy criteria) was 70 percent. Of 150 patients 59 (39 percent) met prostate specific antigen criteria for partial response, and 88 (59 percent) reached treatment failure end points and withdrew. Extent of disease was a significant predictor of response but baseline testosterone was not. Breast pain and gynecomastia developed in 76 percent and 60 percent of patients, respectively. Mean drug plasma concentration was 8,528 plus/minus 2,928 ng./ml. Conclusions: Bicalutamide (50 mg.) daily was well tolerated and efficacious. However, suboptimal effects on prostate specific antigen have led to additional trials to evaluate monotherapy at higher doses.

Published
1995
Full Text
View/download PDF

94. A Randomized Trial of Etoposide + Cisplatin Versus Vinblastine + Bleomycin + Cisplatin + Cyclophosphamide + Dactinomycin in Patients with Good-Prognosis Germ Cell Tumors

Author

Bosl, G.J., primary, Geller, N.L., additional, Bajorin, D., additional, Leitner, S.P., additional, Yagoda, A., additional, Golbey, R.B., additional, Scher, H., additional, Vogelzang, N.J., additional, Auman, J., additional, Carey, R., additional, Fair, W.R., additional, Herr, H., additional, Morse, M., additional, Sogani, P., additional, and Whitmore, W., additional

Published
1989
Full Text
View/download PDF

97. The Prognostic Value of the Pathological Response to Combination Chemotherapy before Cystectomy in Patients with Invasive Bladder Cancer

Author

Splinter, T.A.W., Scher, H.I., Denis, L., Bukowski, R., Simon, S., Klimberg, I., Soloway, M., Vogelzang, N.J., Van Tinteren, H., and Herr, H.

Abstract

The prognostic value of the pathological response to combination chemotherapy of deeply invasive transitional cell cancer of the bladder was retrospectively assessed in 147 patients. Data were collected from 8 different centers. Patients were eligible if they had received intravenous combination chemotherapy followed by partial, total or radical cystectomy, and if they had a minimum followup of 2 years after the start of chemotherapy. Of the patients 90% received methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) or cisplatin plus methotrexate for a median of 3 courses (range 1 to 6). Of the 83 patients who were alive at analysis actuarial median followup was 30.5 months (range 13.2 to 85.6 months). A major pathological response (stage P0, Pis, Pa or P1) was achieved in 41.5% of the patients. Patients with a major pathological response (p stage less than 2) had a 5-year survival of 75% in contrast to 20% for the remaining nonresponding patients (p stage 2 or more). The survival of patients with a major pathological response was independent of whether the response was induced by 2 or more courses of chemotherapy, or whether it was induced by M-VAC in comparison with cisplatin plus methotrexate. Preoperative clinical assessments can identify nonresponding patients correctly and in these cases alternative treatment programs are required, since 80% will die of the disease. Moreover, if neoadjuvant chemotherapy is proved to increase survival, the data emphasize the importance of the response rate of the primary tumor and the need to investigate the optimal number of courses to induce the best response, preferably in the individual patient.

Published
1992
Full Text
View/download PDF

98. Original Articles: Kidney Cancer: Renal Cell Carcinoma: Tumor Size, Stage and Survival

Author

Guinan, P.D., Vogelzang, N.J., Fremgen, A.M., Chmiel, J.S., Sylvester, J.L., Sener, S.F., and Imperato, J.P.

Abstract

In an attempt to define the relationship among tumor size, stage and survival, the Cancer Incidence and End Results Committee of the American Cancer Society, Illinois Division, Inc.reviewed the records of 2,473 patients with a histological diagnosis of renal cell carcinoma. Tumor size was related to stage and survival. Larger tumors were generally associated with an increased stage (p <=0.0005) as well as poorer survival (p <=0.005). For Robson stages II, III and IV, tumor size may contribute additional prognostic information for patient survival.

Published
1995
Full Text
View/download PDF

99. Color Doppler imaging and transrectal sonography of the prostatic fossa after radical prostatectomy: early experience

Author

Sudakoff, G.S., Smith, R., Vogelzang, N.J., Steinberg, G., and Brendler, C.B.

Subjects
Diagnosis, Health aspects, Doppler ultrasonography -- Health aspects, Prostatectomy -- Health aspects, Prostate cancer -- Diagnosis
Abstract

Sudakoff, G.S.; Smith, R.; Vogelzang, N.J.; Steinberg, G.; Brendler, C.B. 'Color Doppler Imaging and Transrectal Sonography of the Prostatic Fossa after Radical Prostatectomy: Early Experience.' American Journal of Roentgenology, October [...]

Published
1996

100. A Phase I cohort of suramin in patients with advanced cancer

Author

Kobayashi, K., Vokes, E.E., Janisch, L., Berezin, F., Vogelzang, N.J., and Ratain, M.J.

Subjects
Testing, Chemotherapy, Prostate cancer, Suramin -- Testing, Cancer -- Chemotherapy, Suramin sodium -- Testing
Abstract

AUTHORS: K. Kobayashi, E.E. Vokes, L. Janisch, F. Berezin, N.J. Vogelzang and M.J. Ratain. University of Chicago Section of Hematology/Oncology, Chicago, Illinois. According to the authors' abstract of a poster [...]

Published
1992

Catalog

Books, media, physical & digital resources
See catalog results